Trials / Terminated
TerminatedNCT01101100
Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis
A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Psoriasis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 181 (actual)
- Sponsor
- Bausch Health Americas, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label extension of study 20090062 to evaluate extended subcutaneous dosing.
Detailed description
This study is an open-label extension of study 20090062 to evaluate extended subcutaneous dosing of AMG 827 for up to 362 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 827 | 210 mg SC or 140 mg SC |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2010-04-09
- Last updated
- 2019-07-30
- Results posted
- 2019-07-18
Locations
21 sites across 5 countries: United States, Australia, Canada, Denmark, France
Source: ClinicalTrials.gov record NCT01101100. Inclusion in this directory is not an endorsement.